Selinexor Support Group Launch
Selinexor Support Group Launch  image
Jan 27, 2021 / 11:00AM - 12:00PM MST
Selinexor Support Group Chapter

Event Description

Are you or a loved one currently taking Selinexor as a part of your myeloma treatment regimen? This is a relatively new drug in the myeloma arsenal and both patients and providers are not very familiar with how to use it in the clinic. We are launching this group to provide support to patients on Selinexor and their caregivers. Hear from Dr. Jatin Shah, CMO of Karyopharm, speak about Selinexor, its approval process, and side effect management. While this event will be a formal presentation, future meetings within this chapter will be more of a casual conversation that will include several patients advocates who will help moderate a group discussion as we cover a wide breadth of Selinexor topics.

Schedule & Agenda

person
Introductions
11:00AM
Audrey Burton-Bethke
The purpose of the chapter is introduced. The featured speaker, Dr. Jatin Shah is introduced.
person
Presentation
11:05AM
Dr. Jatin Shah and Jenny Ahlstrom
Dr. Shah and Jenny details about Selinexor such as what is being learned about side effect management, original FDA approval, and recent approval to move Selinexor into earlier lines of therapy. 
person
Questions and Answers
11:40AM
Bob Sisneros and Audience
Our patient advocate, Bob Sisneros, will open the question and answer session with a couple of questions of his own. We then will open up the questions to the audience through the question and answer section and try to answer as many as we can. 

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Read Bio
The panelist Robert (Bob) Sisneros
Robert (Bob) Sisneros

Bob was diagnosed with myeloma unexpectedly in 2015 through a traumatic experience. After recovering and a failed SCT, he is working his way through other chemotherapy cocktails. Bob is extremely charismatic, loves his wife and family, and is a coach for the Myeloma Crowd if you would like to connect with him. He believes in the power of hope and is a Patient Advocate for our Selinexor Support Group.

Read Bio
The panelist Dr. Jatin Shah
Dr. Jatin Shah

Dr. Jatin Shah, M.D. is the Chief Medical Officer and Executive Vice President of Development at Karyopharm Therapeutics and has been since July of 2019. His responsibilities include the development of study protocols and clinical development plans. He prepares the regulatory documents and provides scientific and clinical input to each of the studies. Prior to that, Dr. Shah acted as Senior VP of Clinical Development and VP of Clinical Strategy at Karyopharm Therapeutics. He is the co-founder of the World Health Forum/World Myeloma Forum that was launched in February of 2017. Before those accomplishments, Dr. Shah was Director of the Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811